<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333888</url>
  </required_header>
  <id_info>
    <org_study_id>2020-513N</org_study_id>
    <nct_id>NCT04333888</nct_id>
  </id_info>
  <brief_title>A Neurofeedback Booster for Emotion Regulation Therapy</brief_title>
  <acronym>BrainBoost</acronym>
  <official_title>BrainBoost - A Neurofeedback Booster for Emotion Regulation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Paret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AE Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof-of-concept study that aims to test the additional value of adjuvant&#xD;
      neurofeedback treatment for psychotherapy. Three sessions of real-time fMRI neurofeedback&#xD;
      will be administered to N=22 patients with BPD while they receive residential Dialectical&#xD;
      Behavior Therapy treatment. In addition, outcomes are assessed from a control group with same&#xD;
      sample size who do not receive the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in affective instability</measure>
    <time_frame>Before treatment, immediately after treatment + follow-up measure (3 months)</time_frame>
    <description>Mean successive squared differences (MSSD) of six-item negative affect scale measured via behavioural sampling using ecological momentary assessment (EMA) over four days. MSSD will be compared between baseline and post-treatment timepoints.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in emotion regulation</measure>
    <time_frame>Before treatment, immediately after treatment + follow-up measure (3 months)</time_frame>
    <description>Negative and neutral pictures are either presented with instruction to regulate or to respond naturally (view). BOLD response in the amygdala (and the rest of the brain) is measured and subjective ratings of regulation success are collected. Changes (between the time points) in differences of the two conditions (regulate vs. view) are measured for both: amygdala BOLD response and subjective ratings of regulation success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in borderline symptomatology</measure>
    <time_frame>Before treatment, immediately after treatment + 2 follow-up measures (3 months, 6 months)</time_frame>
    <description>Facets of BPD are assessed with questionnaires, including impulsivity. Borderline Symptom List (BSL-23) score will be used for assesment of BPD symptoms. This scale has 23 items, each scored 0-4, and total score is mean item endorsement (sum of all items divided by 23). Higher scores indicate more symptom endorsement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in resting state brain connectivity</measure>
    <time_frame>Before treatment, immediately after treatment + follow-up measure (3 months)</time_frame>
    <description>Patients get a 10 min brain scan (fMRI) without active task. Data are analysed to compare changes in intrinsic functional brain connectivity (BOLD activation of amygdala with other brain regions) during resting state before and after neurofeedback training.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in amygdala reactivity</measure>
    <time_frame>Before treatment, immediately after treatment + follow-up measure (3 months)</time_frame>
    <description>Patients will perform a task, in which blocks of faces with negative emotional expressions and scrambled pictures will be presented. This task leads to considerable amygdala activation. With this task, we want to observe effects of neurofeedback on spontaneous amygdala activation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural changes in the brain</measure>
    <time_frame>Before the first neurofeedback training and after the last neurofeedback training</time_frame>
    <description>By including DTI sequences before and after the neurofeedback intervention, we want to explore changes in FA/fiber structure of the brain. (exploratory analysis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Borderline Personality Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Neurofeedback</intervention_name>
    <description>fMRI neurofeedback training of amygdala downregulation</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  DSM-5 BPD diagnosis&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  EtOH and tox negative on the day of neurofeedback&#xD;
&#xD;
          -  BSL-23 score &gt;=1.87 at DBT halftime&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pharmacotherapy with opiates&#xD;
&#xD;
          -  standing benzodiazepines (bedtime-only benzodiazepines and anti-histamines allowed)&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  life-time diagnosis schizophrenia or bipolar disorder I&#xD;
&#xD;
          -  significant current or past neurological illness&#xD;
&#xD;
          -  BMI&lt;16.5&#xD;
&#xD;
          -  usual safety criteria for magnetic resonance imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christian Paret, Dr. sc. hum.</last_name>
    <phone>(+49) 621 - 1703-4462</phone>
    <email>christian.paret@zi-mannheim.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paret</last_name>
      <phone>+49 621 1703</phone>
      <phone_ext>4462</phone_ext>
      <email>christian.paret@zi-mannheim.de</email>
    </contact>
    <investigator>
      <last_name>Miroslava Jindrova, Msc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Zaehringer J, Ende G, Santangelo P, Kleindienst N, Ruf M, Bertsch K, Bohus M, Schmahl C, Paret C. Improved emotion regulation after neurofeedback: A single-arm trial in patients with borderline personality disorder. Neuroimage Clin. 2019;24:102032. doi: 10.1016/j.nicl.2019.102032. Epub 2019 Oct 16.</citation>
    <PMID>31795041</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Central Institute of Mental Health, Mannheim</investigator_affiliation>
    <investigator_full_name>Christian Paret</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

